Literature DB >> 15774504

CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis.

Kakuri M Omari1, Gareth R John, Stuart C Sealfon, Cedric S Raine.   

Abstract

Subsequent to demyelination in multiple sclerosis, myelin repair occurs but, as lesions age, the ability to remyelinate diminishes. Molecular pathways underlying oligodendrocyte behaviour during CNS remyelination remain to be elucidated. In this study, we report for the first time constitutive expression of the CXC/alpha chemokine receptors, CXCR1, CXCR2 and CXCR3, on oligodendrocytes in normal adult human CNS tissue, the levels of which were upregulated in multiple sclerosis and other neurological diseases (OND). In addition, both immature (A2B5+/O4+) and more mature (CNPase+) human oligodendrocytes in vitro expressed the same three receptors. The respective ligands to CXCR1, CXCR2 and CXCR3 [i.e. CXCL8/IL-8, CXCL1/GRO-alpha and CXCL10/IP-10), were absent in CNS tissue from normals and subjects with OND, but were present at high levels on hypertrophic (reactive) astrocytes at the edge of active (but not silent) multiple sclerosis lesions. Astrocytes in vitro could be induced to express chemokines following stimulation with pro-inflammatory cytokines. CXCL8 and CXCL1 production by human astrocytes at both the RNA and protein levels could be induced by interleukin (IL)-1beta, while CXCL10 was induced by both IL-1beta and interferon-gamma. Since these cytokines are integral to inflammatory events occurring at the margins of active multiple sclerosis lesions, their upregulation in these regions may underlie the dynamics of chemokine expression observed herein. The simultaneous expression of different CXC chemokine receptors on oligodendrocytes, and their ligands on astrocytes around multiple sclerosis lesions, may bespeak novel functional roles for these immune system molecules in the recruitment of oligodendrocytes and remyelination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15774504     DOI: 10.1093/brain/awh479

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  77 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  A mouse model of blast-induced mild traumatic brain injury.

Authors:  Vardit Rubovitch; Meital Ten-Bosch; Ofer Zohar; Catherine R Harrison; Catherine Tempel-Brami; Elliot Stein; Barry J Hoffer; Carey D Balaban; Shaul Schreiber; Wen-Ta Chiu; Chaim G Pick
Journal:  Exp Neurol       Date:  2011-09-17       Impact factor: 5.330

Review 3.  Control of autoimmune CNS inflammation by astrocytes.

Authors:  Veit Rothhammer; Francisco J Quintana
Journal:  Semin Immunopathol       Date:  2015-07-30       Impact factor: 9.623

Review 4.  Remyelination strategies: new advancements toward a regenerative treatment in multiple sclerosis.

Authors:  Martin Stangel; Corinna Trebst
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

Review 5.  Autoimmune modulation of astrocyte-mediated homeostasis.

Authors:  Thomas Korn; Mahendra Rao; Tim Magnus
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

6.  Multiple sclerosis: death receptor expression and oligodendrocyte apoptosis in established lesions.

Authors:  Barbara Cannella; Stefanie Gaupp; Kakuri M Omari; Cedric S Raine
Journal:  J Neuroimmunol       Date:  2007-07-05       Impact factor: 3.478

7.  Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1.

Authors:  Kakuri M Omari; Sarah E Lutz; Laura Santambrogio; Sergio A Lira; Cedric S Raine
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

Review 8.  Neuroprotection and neuroregeneration in multiple sclerosis.

Authors:  Martin Stangel
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

Review 9.  Oligodendrocyte-microglia cross-talk in the central nervous system.

Authors:  Laura Peferoen; Markus Kipp; Paul van der Valk; Johannes M van Noort; Sandra Amor
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

10.  SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.

Authors:  George P Christophi; Chad A Hudson; Ross C Gruber; Christoforos P Christophi; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2008-01-21       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.